February 7, 2025 Experience McKesson $850 million acquisition of controlling interest in PRISM Vision We are advising McKesson on the transaction
January 28, 2025 Experience Ascentage Pharma $126.4 million IPO The IPO is the first life sciences U.S. IPO of 2025 and the first life sciences company listed on the HKEX to complete a U.S. listing
January 13, 2025 Experience GSK up to $1.15 billion acquisition of IDRx We are advising GSK on the transaction
January 13, 2025 Experience Intra-Cellular Therapies $14.6 billion acquisition by Johnson & Johnson We are advising Intra-Cellular Therapies on the transaction
January 7, 2025 Experience Teoxane proposal to acquire Revance Therapeutics We are advising Teoxane on the proposed acquisition
December 4, 2024 Experience Cross Country Healthcare $615 million acquisition by Aya Healthcare We are advising Cross Country Healthcare on the transaction
November 12, 2024 Experience GSK strategic alliance with Vesalius Therapeutics We advised GSK on the transaction
September 17, 2024 Experience MBX Biosciences $188 million IPO The shares are listed on the Nasdaq Global Select Market
August 26, 2024 Experience McKesson $2.49 billion acquisition of controlling interest in Core Ventures We are advising McKesson on the transaction